Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

436 results about "Nephritis" patented technology

Inflammation of the kidneys that may involve the glomeruli, tubules or interstitial tissue surrounding them.

Ultrasonic cavitation control method for nephritis physiotherapy

The invention belongs to the technical field of ultrasonic waves, and particularly relates to a nephritis physiotherapy-oriented ultrasonic cavitation control method, which comprises the following steps of: generating a renal ultrasonic image by using a three-dimensional imaging probe and collecting echo information; ultrasonic cavitation characteristics are extracted to monitor the cavitation degree in real time, a sound field and biological information are obtained by combining ultrasonic images and echo information, and calculation and normalization processing of multi-angle cavitation indexes are carried out; processing an ultrasonic image to obtain kidney position information, configuring delay parameters for a physiotherapy array, fusing normalized cavitation indexes to establish an evaluation equation, adjusting index weights according to cavitation monitoring information, guiding selection of ultrasonic amplitude-frequency parameters, and ensuring that the cavitation degree of a focusing area is in an ideal range; and encoding the time delay and amplitude-frequency parameter information to configure an excitation signal for the physiotherapy array, and transmitting ultrasonic waves. According to the method, monitoring of the cavitation effect and nephritis physical therapy can be coordinated, the medicine penetrating capacity is improved through the controllable cavitation effect, and the nephritis physical therapy effect is improved.
Owner:CHANGCHUN UNIV OF SCI & TECH

Probiotic fermentation composition with memory improving function and preparation method thereof

The invention relates to a probiotic fermentation composition with a memory improving function and a preparation method thereof, semiliquidambar cathayensis and bulbophyllum herb have the potential of treating cell injury, cassia mimosa has the effects of clearing away heat and toxic materials, and pogonatherum crinitum can treat urinary tract infection, hepatitis, nephritis and spleen inflammation. According to the invention, semiliquidambar cathayensis, bulbophyllum, cassia mimosa and pogonatherum crinitum are respectively taken as efficacy combinations, exploration in the aspect of cognitive function improvement is carried out, a unique new product preparation mode, namely, unconventional traditional Chinese medicines are fermented by enzymatic probiotics, and the melt beans are prepared by freeze drying. The composition is scientific and reasonable in raw material matching, good in palatability, free of preservatives, artificial colors and synthetic flavors and fragrances, safe in quality and formed by natural fermentation and enzymolysis of beneficial bacteria. The dose-effect relationship among the raw materials is fully mastered, the process is simple, the medicine is convenient to take, the bioavailability is high, and the effect of improving the memory function is fully exerted.
Owner:NINGBO YUYI BIOTECHNOLOGY CO LTD

Method for constructing Ddx58-R109C point mutation mouse model and application of Ddx58-R109C point mutation mouse model

The invention discloses a method for constructing a Ddx58-R109C point mutation mouse model by using a CRISPR / Cas9 gene editing technology and an application of the Ddx58-R109C point mutation mouse model. The method comprises the following steps: (1) target construction: searching a CDS region of a Ddx58 gene, determining an exon part, and determining a gene mutation site; (2) obtaining a fertilized egg, and injecting Cas9mRNA, gRNA and donor oligo into the fertilized egg of the C57BL / 6J mouse together in vitro through a microinjection technology to obtain an F0-generation hybrid mouse; (3) mating the F0-generation hybrid mouse with the wild type mouse to obtain an F1-generation mouse; (4) the F1-generation heterozygous mice which are identified to be positive are subjected to mating, and homozygous Ddx58-R109C mutant type and wild type mice can be obtained by breeding obtained offspring; (5) phenotypic analysis shows that Ddx58-R109C point mutation mice can have pathological changes of systemic lupus erythematosus and lupus nephritis; the invention can provide an effective research approach and method for researchers to deeply explore the action mechanism of Ddx58-R109C mutation in diseases, and has important significance for explaining the pathogenesis of systemic lupus erythematosus and researching and developing targeted therapeutic drugs.
Owner:NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A

Complement component C3 iRNA compositions and methods of use thereof

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the complement component C3 gene (C3). The invention also relates to methods of using such RNAi agents to inhibit expression of a C3 gene and to methods of preventing and treating a C3-associated disorder, e.g., cold agglutinin disease (CAD), warm autoimmune hemolytic anemia, and paroxysmal nocturnal hemoglobinuria (PNH), lupis nephritis (LN), bullous pemphigoid, Pemphigus, e.g., Pemphigus vulgaris (PV) and Pemphigus foliaceus (PF), and C3 glomerulopathy.
Owner:ALNYLAM PHARMACEUTICALS INC

Method for constructing differential diagnosis model of lupus nephritis and membranous nephropathy

The invention discloses a method for constructing a differential diagnosis model for lupus nephritis and membranous nephropathy, and belongs to the technical field of intelligent medical treatment. The modeling method comprises the following steps: S1, respectively collecting flow cytometry detection data of lupus nephritis patients and healthy control personnel; s2, performing data cleaning and conversion on the flow cytometry detection data, and converting non-numerical features into digits; carrying out implication on the missing value by adopting a k nearest neighbor algorithm from an implication packet; s3, random sampling is carried out on the cleaned and converted data set, and samples are divided into a training set and a verification set according to the proportion of 7: 3; s4, dividing a training subset and a test set from the training set, and iteratively selecting the types of cells incorporated into the constructed model as pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T, and CD38 + PD-1 + CD8T by adopting an RFE method, wherein the types of the cells incorporated into the constructed model are pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T and CD38 + PD-1 + CD8T; and S5, performing a classification task by adopting TabPFNClassifier, performing training from features selected from the training data set, then evaluating the performance of the model, performing model training by utilizing detection data, and performing evaluation to construct a lupus nephritis prediction model with high accuracy.
Owner:BEIJING HOSPITAL

Flavonoid active fraction of an abelmoschi corolla, preparation method and application thereof

The invention relates to a flavonoid active fraction of an Abelmoschi corolla, a preparation method and an application thereof, and belongs to the field of traditional Chinese pharmaceutics. A high-purity Abelmoschi corolla flavonoid active fraction is prepared, which is found to have better therapeutic activity for kidney disease, and especially have a significant therapeutic effect for diabetic kidney disease and lupus nephritis, or contrast-induced kidney injury and eye diseases. Meanwhile, the Abelmoschi corolla flavonoid active fraction described in the invention also has good safety.
Owner:SUZHONG PHARMACEUTICAL GROUP CO LTD +1

Application of intervening basophilic granulocyte EXOSC3 in preparation of medicine for preventing or treating lupus nephritis

The invention belongs to the technical field of biological medicines, and discloses an application of intervening basophilic granulocyte EXOSC3 in preparation of a medicine for preventing or treating lupus nephritis, which comprises knocking down or knocking out the expression of EXOSC3. The invention finds that the expression of EXOSC3 is enhanced after basophilic granulocyte activation, and the expression is reduced after activation inhibition. After the EXOSC3 of the basophilic granulocyte is knocked down, the expression levels of inflammatory factors IL-4, IL-6 and IL-13 of the basophilic granulocyte are obviously reduced. After the basophilic granulocyte knock-down EXOSC3 and T cells are co-cultured, the activation level of the T cells is obviously reduced. After the basophilic granulocytes knocking down the Exosc3 are adoptively transferred into a lupus mouse body, the kidney pathology is obviously improved. The invention proves that the knock-down basophilic granulocyte EXOSC3 can obviously inhibit the activation of the basophilic granulocyte EXOSC3 and improve the kidney pathology of lupus mice, thereby providing a new thought for the treatment of basophilic granulocyte activation-mediated lupus diseases.
Owner:AFFILIATED HOSPITAL OF GUANGDONG MEDICAL UNIV

Application of eriochin in preparation of medicine for preventing and treating GBM crescent nephritis and proteinuria of GBM crescent nephritis

The invention belongs to the technical field of kidney pathology and pharmacology, and particularly relates to application of Forskolin in preparation of a medicine for preventing and treating GBM crescent nephritis and proteinuria of the GBM crescent nephritis. The NTS-induced podocyte injury is characterized by WT1 down-regulation, and Forskolin can directly up-regulate WT1, so that Forskolin is prompted to be capable of antagonizing podocyte dedifferentiation so as to relieve the injury; as an activator of adenylate cyclase, the Forskolin can inhibit STAT3, p53, NF [kappa] B, FAK and TGF-beta pathways in mechanism, and meanwhile, can up-regulate essential genes WT1, SYNPO and VEGFA of podocyte; forskolin can replace glucocorticoid to treat podocyte damage and proteinuria, the Forskolin can protect podocytes by directly inhibiting harmful pathways and related genes, and meanwhile, expression of essential genes of the podocytes is enhanced without being damaged, so that the Forskolin has the efficacy equivalent to that of the glucocorticoid in an NTS treated mouse; forskolin can replace glucocorticoid to treat anti-GBM glomerulonephritis so as to avoid side effects of the anti-GBM glomerulonephritis.
Owner:NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A

Circular RNA encoding cars and the use thereof

Provided is a circular RNA encoding CARs and the use thereof to create immune cells that target specific diseases, e. g., lymphoma, multiple myeloma and leukemia and auntoimmune diseases, such as systemic lupus erythematousus, lupus nephritis and myasthenia gravis.
Owner:THERORNA SHANGHAI CO LTD

Compositions and methods of treating lupus nephritis

The present disclosure provides methods for treating lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the present disclosure provides methods for treating membranous nephropathy.
Owner:GENENTECH INC

A Chinese medicine composition for treating IgA nephropathy and preparation method thereof

ActiveCN115531484BMedicinal propertiesMedicinal and calmFungi medical ingredientsUrinary disorderAdverse drug reactionWolfiporia extensa
The present invention provides a Chinese medicine composition for treating IgA nephropathy and a preparation method thereof, and belongs to the technical field of Chinese medicine compositions. The Chinese medicine composition of the present invention comprises raw rehmannia, astragalus, caesalpinia, codonopsis, radix rehmanniae, ophiopogon, plantago, tuckahoe, scutellaria, umbellate, motherwort, bupleurum, oldenlandia diffusa, scutellaria barbata, caulis scabra, radix scutellariae, radix scutellariae, radix licorice. The present invention also provides a preparation method of the Chinese medicine composition, comprising: weighing the raw materials according to the raw material ratio, decocting with water, and filtering to obtain a medicinal liquid. The composition provided by the present invention has a mild medicinal property, clears the heart fire, replenishes qi and yin, has no toxic side effects, can effectively reduce hematuria, proteinuria and adverse drug reactions, and is used for the treatment of chronic glomerulonephritis (IgA nephropathy).
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Membrane nephropathy marker and application thereof

The invention provides an application of a reagent for detecting an effector CD4 + T cell in peripheral blood of a subject in preparation of a product for diagnosing membranous nephropathy, lupus nephritis or ANCA-related vasculitis. The invention also provides an application of the effector CD4 + T cell in peripheral blood in preparation of a diagnostic model for diagnosing membranous nephropathy, lupus nephritis or ANCA-related vasculitis. The marker is detected through flow cytometry, and the result shows that the Ejector CD4 + T cell is remarkably increased in a patient with membranous nephropathy, can effectively distinguish membranous nephropathy from healthy control (verification set AUC 0.8098), can assist in identifying membranous nephropathy, lupus nephritis (verification set AUC 0.8686) and ANCA-related vasculitis (verification set AUC 0.8968), and the level of the Ejector CD4 + T cell is related to whether membranous nephropathy is difficult to treat or not.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Marker for lupus nephritis and application thereof

The invention discloses a lupus nephritis marker and application thereof, and belongs to the technical field of biomarkers. The marker for the lupus nephritis, disclosed by the invention, comprises one or more of CD8, CD38 and PD-1. By detecting specific cell surface markers in patient blood, early diagnosis of LN is assisted in a minimally invasive mode, and based on deep comparative analysis of LN patients and healthy people, the specificity and sensitivity of the biomarkers in LN diagnosis are ensured through screening of the biomarkers. In the aspect of differential diagnosis, a clinician is assisted to distinguish LN from other types of kidney diseases, such as membranous nephropathy (MN) and anti-neutrophil cytoplasm antibody related vasculitis (AAV), by analyzing specific biomarker modes of different nephropathy. The dependence on kidney puncture is reduced, related potential risks and inconvenience are avoided, and meanwhile more accurate and timely diagnosis is provided for an SLE patient.
Owner:BEIJING HOSPITAL

IRNA compositions and methods for silencing complement component 3 (C3)

PendingUS20250019698A1Organic active ingredientsScreening processMotor neuropathyC3 Glomerulonephritis
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting a complement component C3 (C3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a C3 gene and to methods of preventing and treating a C3-associated disorder, e.g., paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), atypical hemolytic uremic syndrome (aHUS), neuromyelitis optica (NMO), multifocal motor neuropathy (MMN), myasthenia gravis (MG), C3 glomerulonephritis, or systemic lupus erythmatosis.
Owner:ALNYLAM PHARMACEUTICALS INC

Double-stranded siRNA analogue for inhibiting MASP2 expression as well as preparation method and application of double-stranded siRNA analogue

The present invention relates to a double-stranded siRNA analogue for inhibiting expression of mannan-binding lectin-related serine protease 2 (MASP2), and a preparation method and use thereof, the double-stranded siRNA analogue can inhibit expression of MASP2, and is used for preventing and / or treating MASP2-related diseases and symptoms, such as MASP2-related diseases and disorders. The diseases and symptoms comprise IgA nephropathy, membranous nephropathy, lupus nephritis, thrombotic microangiopathy, systemic lupus erythematosus and the like.
Owner:SHENZHEN SALUBRIS PHARMA CO LTD

Use of phlorizin in the treatment and / or prevention of lupus nephritis

The application of phlorizin in the medicine for treating and / or preventing lupus nephritis, the molecular formula of phlorizin is C 21 H 24 O 10 , the application promotes the differentiation of regulatory T cells (Treg) by applying phlorizin to up-regulate the PI3K / Akt signal pathway, thereby reducing the symptoms of lupus nephritis, and provides an effective treatment method with less side effects. In the application, the traditional Chinese medicine monomer phlorizin can effectively promote the differentiation of Treg cells, and compared with compound traditional Chinese medicine, the use of single component has more advantages in drug efficacy control and efficacy evaluation. In addition, phlorizin is widely sourced, low in cost and non-toxic, and is very suitable for long-term treatment of lupus nephritis.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

How to Use Factor B Inhibitors

Disclosed herein is a method for treating immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) with the factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof (e.g., iptacopan hydrochloride).
Owner:NOVARTIS AG

Antrodia camphorata sporocarp extract

The invention provides an antrodia camphorata sporocarp extract, which is prepared from the following raw materials in parts by weight: 20 to 24 parts of wild ganoderma lucidum extract, 8 to 12 parts of herba taraxaci and 8 to 12 parts of bolete. The antrodia camphorata sporocarp extract disclosed by the invention contains various physiologically active components such as triterpenoids, polysaccharides, superoxide disproportionated enzymes, adenosine, proteins (containing immune proteins), vitamins, trace elements, nucleic acid, lectin, amino acid, sterols, lignin, blood pressure stabilizing substances and the like; the traditional Chinese medicine composition can relieve various tumors such as hangover, gastrointestinal discomfort, heatstroke, hypertension, virus infection, diabetes mellitus, nephritis, liver cirrhosis and liver cancer, has the effects of resisting oxidation, resisting inflammation, inhibiting hypertension, protecting liver nerves, inhibiting tumor growth and the like, can bidirectionally regulate immunity and protect the liver, can also treat tumors at multiple targets, and has a wide application prospect. The discomfort of a patient in an anti-tumor process is reduced.
Owner:TIANJIN CLOUD LADDER ENTERPRISE MANAGEMENT CONSULTING CO LTD

Application of pharmaceutical composition in preparation of nephropathy drugs

The invention discloses application of a pharmaceutical composition in preparation of a medicine for treating nephropathy, the nephropathy is at least one of membranous glomerulonephritis, postoperative acute kidney injury caused by non-contrast agents, immunoglobulin A nephropathy, purpura nephritis and idiopathic focal segmental glomerulosclerosis, and the pharmaceutical composition belongs to the technical field of pharmacy. The pharmaceutical composition is prepared from the following flavonoid components in a mass ratio: the mass ratio of the gossypothelin-8-O-beta-D-glucuronide to the hyperoside to the isoquercitrin to the myricetin to the quercetin-3 '-O-glucoside is 10 to (3.0 to 20) to (2.0 to 18) to (0.2 to 6.0) to (1 to 20). The pharmaceutical composition has obvious effects of preventing and / or treating membranous glomerulonephritis, postoperative acute kidney injury caused by non-contrast agents, immunoglobulin A nephropathy, purpura nephritis and idiopathic focal segmental glomerulosclerosis, and has relatively good safety.
Owner:SUZHONG PHARMACEUTICAL GROUP CO LTD +2

Matrix metalloproteinase (MMP) inhibitors and methods of use thereof

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.
Owner:FORESEE PHARMACEUTICALS USA INC

Methods of using factor b inhibitors

Described herein are methods of treating immune complex mediated membrane proliferative glomerulonephritis (IC-MPGN) with a factor B inhibitor ipropam or a pharmaceutically acceptable salt thereof, e.g., ipropam hydrochloride.
Owner:NOVARTIS AG

Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and β1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly, CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritides.
Owner:UNIV PARIS CITE +2

Treatment of lupus nephritis with Anti-type i inf receptor antibody anifrolumab

The disclosure relates to methods and compositions for the treatment of lupus nephritis (LN) with anti-type I IFN receptor inhibitor antibody Anifrolumab. Results of clinical trials with intravenous and subcutaneous administration of Anifrolumab. Identification of markers for LN and delivery devices and pre-filled syringe for administration of Anifrolumab.
Owner:ASTRAZENECA AB

Application of TINAGL1 in the preparation of anti-hepatic fibrosis drugs and new uses of compounds

ActiveCN118641765BCompound screeningApoptosis detectionTubulointerstitial nephritis antigenPharmaceutical drug
The present invention belongs to the field of medicine and discloses the use of tubulointerstitial nephritis antigen-like protein 1 (TINAGL1) as a direct target for screening anti-hepatic fibrosis drugs. By using TINAGL1 as a direct target, target drugs that can bind to human TINAGL1 recombinant protein can be screened out. These target drugs have been proven to be able to reduce the increase in the level of the fibrosis factor COL1A1 in LX-2 cells induced by PDGF-BB and can achieve anti-hepatic fibrosis effects to varying degrees. At the same time, the present invention also discloses a screening method for anti-hepatic fibrosis drugs, new potential anti-hepatic fibrosis drugs, and new uses of compounds.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI

A biomarker for evaluating progression of systemic lupus erythematosus to lupus nephritis, a prediction model and application thereof

The application discloses a kind of biomarkers for evaluating systemic lupus erythematosus to lupus nephritis progression, prediction model and application, belong to lupus nephritis prediction technical field.The application provides a kind of for evaluating systemic lupus erythematosus to lupus nephritis progression prediction model, the prediction model is according to the ratio of biomarker CD8 / CD4 and the κ / λ ratio of naive B cell, carries out binary Logistic regression analysis, obtains LogitP value, by comparing the high and low of the LogitP value and critical value 0.66938, predicts systemic lupus erythematosus to lupus nephritis progression situation.The prediction model constructed in the application aims to identify the individuals in lupus patients who may develop into lupus nephritis.This innovative model not only provides important guidance in the diagnosis, prognosis prediction and efficacy evaluation of the disease, but also provides a new perspective for the clinical management of lupus nephritis.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Diagnostic marker for ANCA-related vasculitis

The invention discloses a diagnostic marker for ANCA (Angiovasculitis) related vasculitis. It is found for the first time that the CD19 + CD38 + CD27-CD24 + cell can be used as the diagnosis marker of ANCA related vasculitis, and the diagnosis efficiency is high; in addition, it is found that the CD19 + CD38 + CD27-CD24 + cells can remarkably distinguish ANCA related vasculitis and membranous nephropathy or ANCA related vasculitis and lupus nephritis, a new direction is provided for diagnosis and subsequent treatment of ANCA related vasculitis, and the application has wide application prospects clinically.
Owner:BEIJING HOSPITAL

Lupus nephritis condition monitoring system based on dynamic change of TWEAK and CD163

The invention relates to the field of medical care informatics, and discloses a lupus nephritis condition monitoring system based on TWEAK and CD163 dynamic change, which comprises a data adaptation gateway module, a data rationality arbitration engine, a time sequence regularization engine module, a high-order feature extraction engine module and a risk layering module, the time sequence regularization engine module switches an interpolation or smoothing algorithm based on a qualitative result of the data rationality arbitration engine and a time domain where a data point is located so as to generate a continuous time function. Through the information processing architecture, the technical problem that sparse asynchronous original medical data is prone to being affected by outlier pollution and end point distortion is solved, and the accuracy of data processing is improved. The system reconstructs discrete data snapshots into continuous mathematical objects, provides a stable and analyzable technical basis for subsequent extraction of interpretable high-order dynamic features, and improves the credibility of clinical decision support.
Owner:南昌大学第一附属医院

RNAi agent for inhibiting complement factor B (CFB) expression, pharmaceutical composition thereof, and method of use

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.
Owner:ARROWHEAD PHARMACEUTICALS INC